Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates and atherosclerosis: why?

M Bevilacqua1, L J Dominguez, S Rosini

  • 1Endocrine and Diabetes Unit, Ospedale L Sacco, Vialba, University of Milan, Italy. mauriziobevilacqua@fastwebnet.it

Lupus
|October 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolomic profiling of pancreatic juice: a potential prognostic tool for pancreatic ductal adenocarcinoma.

Surgical oncology·2026
Same author

Augmented Reality PSMA-3D guided robotic pelvic lymph node dissection (PLND) in prostate cancer patients.

Prostate cancer and prostatic diseases·2025
Same author

Reperfusion failure after successful thrombectomy of large vessel occlusion stroke: clinical and imaging evidence.

Frontiers in neurology·2025
Same author

Bone marrow edema in osteoarthritis and bone trauma. Diagnose and treatment.

La Clinica terapeutica·2025
Same author

Physiopathology and pharmacological protection of periprosthetic bone.

La Clinica terapeutica·2025
Same author

Shedding Light on the Origin of ^{204}Pb, the Heaviest s-Process-Only Isotope in the Solar System.

Physical review letters·2024
Same journal

Association of GPX4 rs713041 and rs4807542 polymorphisms and serum GPX4 levels in Chinese patients with systemic lupus erythematosus.

Lupus·2026
Same journal

Giant cell myocarditis in an 18-year-old patient with new-onset systemic lupus erythematosus: A fatal case of rapidly progressing heart failure.

Lupus·2026
Same journal

An evidence-based specialist nursing protocol for children with hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) and its application research.

Lupus·2026
Same journal

T-bet expression in B cell subsets: Association with T peripheral helper cells and clinical activity in systemic lupus erythematosus.

Lupus·2026
Same journal

Autonomic dysfunction in systemic lupus erythematosus and systemic sclerosis.

Lupus·2026
Same journal

Recent advances in the management of pediatric neuropsychiatric lupus from conventional therapies to novel immunomodulators.

Lupus·2026
See all related articles

Bisphosphonates, used for osteoporosis, may also treat atherosclerosis by inhibiting arterial calcification and lipid accumulation. Further clinical research is needed to confirm these potential dual benefits.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Bone calcification processes share similarities with vascular calcification, a contributor to cardiovascular diseases like heart failure and hypertension.
  • Bisphosphonates are widely used to treat bone resorption diseases such as osteoporosis by inhibiting osteoclasts.

Purpose of the Study:

  • To explore the potential of bisphosphonates in treating atherosclerosis.
  • To investigate the mechanisms by which bisphosphonates might inhibit vascular calcification and related cardiovascular issues.

Main Methods:

  • Review of existing studies on bisphosphonates' effects on experimental atherosclerosis.
  • Analysis of proposed mechanisms including inhibition of arterial calcification, lipid accumulation, LDL-cholesterol degradation, and macrophage suppression.

Related Experiment Videos

Main Results:

  • Specific bisphosphonates (etidronate, pamidronate, clodronate) have shown inhibition of experimental atherosclerosis.
  • Proposed mechanisms involve inhibiting cholesterol biosynthesis enzymes and suppressing macrophages in atheromatous lesions.

Conclusions:

  • Bisphosphonates demonstrate potential for treating both osteoporosis and atherosclerosis.
  • Current evidence is not conclusive, and further clinical research is necessary to validate these findings.